These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22425607)

  • 1. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
    Lemos Duarte I; da Silveira Nogueira Lima JP; Passos Lima CS; Deeke Sasse A
    Breast; 2012 Jun; 21(3):343-9. PubMed ID: 22425607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
    Jacquin JP; Jones S; Magné N; Chapelle C; Ellis P; Janni W; Mavroudis D; Martín M; Laporte S
    Breast Cancer Res Treat; 2012 Aug; 134(3):903-13. PubMed ID: 22270929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
    Petrelli F; Cabiddu M; Coinu A; Borgonovo K; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2015 Jun; 151(2):251-9. PubMed ID: 25917869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
    Zhou W; Chen S; Xu F; Zeng X
    World J Surg Oncol; 2018 Jul; 16(1):144. PubMed ID: 30007402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Bonilla L; Ben-Aharon I; Vidal L; Gafter-Gvili A; Leibovici L; Stemmer SM
    J Natl Cancer Inst; 2010 Dec; 102(24):1845-54. PubMed ID: 21098761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
    Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
    Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
    Goldvaser H; Majeed H; Ribnikar D; Šeruga B; Ocaña A; Cescon DW; Amir E
    Breast Cancer Res Treat; 2018 Jun; 169(3):413-425. PubMed ID: 29423899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
    Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C; Blondeaux E; De Laurentiis M; Valle E; Cognetti F; Nisticò C; De Placido S; Garrone O; Gamucci T; Montemurro F; Puglisi F; Cardinali B; Fregatti P; Miglietta L; Boccardo F; Ceppi M; Del Mastro L;
    Eur J Cancer; 2020 Sep; 136():43-51. PubMed ID: 32634760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
    Poggio F; Ceppi M; Lambertini M; Bruzzi P; Ugolini D; Bighin C; Levaggi A; Giraudi S; D'Alonzo A; Vaglica M; Blondeaux E; Sertoli MR; Pronzato P; Del Mastro L
    Breast; 2017 Jun; 33():104-108. PubMed ID: 28360014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Chen G; Guo Z; Liu M; Yao G; Dong J; Guo J; Ye C
    Oncol Res; 2017 Nov; 25(9):1567-1578. PubMed ID: 28337954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
    De Laurentiis M; Cancello G; D'Agostino D; Giuliano M; Giordano A; Montagna E; Lauria R; Forestieri V; Esposito A; Silvestro L; Pennacchio R; Criscitiello C; Montanino A; Limite G; Bianco AR; De Placido S
    J Clin Oncol; 2008 Jan; 26(1):44-53. PubMed ID: 18165639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
    Zhang ZC; Xu QN; Lin SL; Li XY
    PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
    Chen L; Zhou W; Hu X; Yi M; Ye C; Yao G
    Cancer Treat Rev; 2019 May; 75():12-19. PubMed ID: 30856373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
    J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
    Santos LV; Cruz MR; Lopes Gde L; Lima JP
    Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
    Gyawali B; Niraula S
    Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
    Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
    Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.